Competitive grant funding for academic institutions, public bodies, and third sector organisations in Scotland to support initiatives that will help Scottish SMEs improve their manufacturing capabilities. About the fund Academic institutions, public bodies, and third sector organisations in Scotland can receive competitive grant funding to support initiatives that will help small and medium-sized enterprises (SMEs) in Scotland improve their manufacturing capabilities. Up to £14 million...
More than £250 million growth deal set to bring jobs and opportunity to the Ayrshire region for years to come. On the 8th of March 2019, Scottish Secretary David Mundell was joined by council leaders and the Scottish Government’s Cabinet Secretary for transport, infrastructure and connectivity, Michael Matheson, to sign a transformational growth deal for Ayrshire. The deal will see the UK government invest £103...
RoslinCT, a leading cell and gene therapy contract manufacturing organisation, is delighted to announce the appointment of Ian McCubbin OBE to the Board of Directors. Ian is a prominent figure within the Advanced Therapy community and brings a wealth of industry experience to the position. Ian will be able to bring his global manufacturing and supply chain experience and his strategic approach to the board....
SYMBIOSIS Pharmaceutical Services, a fast-growing specialist sterile manufacturing CDMO, has reported FDA approval for its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK. Symbiosis recently hosted a successful inspection by the United States Government Food and Drug Administration (FDA) for the aseptic manufacture of viral vector products for commercial supply into the U.S market at its GMP manufacturing facility,...
Merck, a life science facility in Irvine has had a £1.3million expansion. The expansion allows Merck to now supply materials for cutting edge medicines tackling diseases including Alzheimer’s, rheumatoid arthritis, cancer, flu, diabetes and dementia medicines. The facility produces both liquid and powder cell culture media which is of vital importance to their global network. To read the full article, click here.
Pharmaceutical giant GSK has unveiled its £44 million vaccine production facility in Montrose. The site, which will produce ingredients for vaccines to treat conditions such as tetanus, pneumonia and whooping cough, has been five years in the making. GSK had first announced plans for its facility, which is now being commissioned, in 2012. The facility will create a further 19 skilled jobs in Montrose by...